ALKERMES INC
Healthcare · Pharmaceutical Preparations · PA · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY11 | FY10 | FY09 | |
|---|---|---|---|
| Revenue | $186.6M | $178.3M | $326.8M |
| Operating income | −$45.6M | −$43.0M | $135.0M |
| Net income | −$45.5M | −$39.6M | $130.5M |
| Total assets | $452.4M | $515.6M | — |
| Total liabilities | $60.4M | $103.0M | — |
| Equity | $392.0M | $412.6M | $434.9M |
| EPS (diluted) | $-0.48 | $-0.42 | $1.36 |
| Shares out. | 95.7M | 94.9M | 96.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2011- Operating margin
- −24.4%
- Net margin
- −24.4%
- Return on equity
- −11.6%
- Return on assets
- −10.1%
- Return on capital (ROCE)
- −11.3%
- Liabilities / assets
- 13.4%
- Debt / equity
- 0.15×
- Book value / share
- $4.09
- Revenue growth (YoY)
- 4.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2011- Altman Z″ (distress)
- 6.14safe
- Accruals / assets
- −8.8%clean
- Beneish M-Score
- -2.50normal
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 4 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗May 29, 2007
- NT 10-Qmissed a reporting deadline ↗Aug 10, 2006
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
FDA-approved drugs
openFDA · most recent- VIVITROLApr 13, 2006
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Recruitingreadout ~2026-06A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia
- Phase 3Recruitingreadout ~2026-09Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
- Phase 3Recruitingreadout ~2027-05A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
- Phase 3Recruitingreadout ~2027-05A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
- Phase 3Recruitingreadout ~2027-06A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)
- Phase 3Enrolling By Invitationreadout ~2027-09Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
- Phase 2/3Recruitingreadout ~2028-06A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Material events
SEC Form 8-K · most recent- Shareholder vote · Other material eventSep 8, 2011
- Results of operations · Other material eventAug 1, 2011
- Results of operations · Other material eventJul 18, 2011
- Director / officer changeMay 19, 2011
- Results of operations · Other material eventMay 18, 2011
- Results of operations · Other material eventMay 9, 2011
- Entered a material agreement · Regulation FD disclosure · Other material eventMay 9, 2011
- Regulation FD disclosureApr 15, 2011
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- CT ORDERMay 19, 2020
- CT ORDERMar 18, 2019
- CT ORDERFeb 19, 2016
- SC 13G/AALKS AS OF 12/31/2015Feb 11, 2016
- CT ORDERJan 11, 2016
- SC 13G/AALKS AS OF 12/31/2013Feb 11, 2014
- SC 13G/AALKS AS OF 12/31/12Feb 11, 2013
- SC 13GALKS AS OF 03/31/2012Apr 10, 2012
- SC 13G/AALKS AS OF 12/31/11Feb 13, 2012
- SC 13G/AFeb 10, 2012
- SC 13G/AFeb 9, 2012
- SC 13G/ADec 8, 2011
- SC 13DALKERMES SCHEDULE 13DSep 26, 2011
- 4PRIMARY DOCUMENTSep 20, 2011
- 4PRIMARY DOCUMENTSep 20, 2011